Mirum Pharmaceuticals
MIRM----
Mirum Pharmaceuticals (MIRM)
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan d...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Mirum Pharmaceuticals Analyst Rating
View MoreForecast & Rating
Jul 27, 2026Price forecast
$146.5027.20%
Forecast & RatingStrong buy
13analysts
- Strong buy69.23%
- Buy30.77%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Jul 23 at 02:26 AM
Mirum Pharmaceuticals (MIRM) Projected to Announce Quarterly Earnings on Thursday
- StockTitan · Jul 13 at 07:01 AM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | MIRM Stock News
- PUBT · Jul 8 at 04:10 PM
Mirum CFO Eric Bjerkholt disposes of common shares worth $609,156.6
- PUBT · Jul 2 at 05:01 PM
Mirum SVP, Global Controller Jolanda Howe disposes of 2,721 common shares worth $326,520
- Market Beat · Jul 2 at 09:42 AM
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $125.00 at JPMorgan Chase & Co.
- Quartr · Jul 1 at 05:24 PM
MIRM: Robust sales growth and a rich late-stage pipeline position the company for five potential approvals by 2027
